版本:
中国

BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A

May 22 Xenetic Biosciences Inc

* Xenetic Biosciences - receives program update from partner Shire's phase 1/2 study evaluating SHP656 in development as a long-acting treatment for Hemophilia A

* Xenetic Biosciences Inc says additionally, there were no drug-related adverse events, serious adverse events, or RFVIII inhibitors reported

* Xenetic Biosciences Inc - "not achieving principal objective of once-weekly dosing in this Phase 1/2 study" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐